(Q44769720)

6 December 2017

title

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model (English)

1 reference

6 December 2017

R Mark Buller

1

1 reference

6 December 2017

Gelita Owens

2

1 reference

6 December 2017

Jill Schriewer

3

1 reference

6 December 2017

Lora Melman

4

1 reference

6 December 2017

James R Beadle

5

1 reference

6 December 2017

Karl Y Hostetler

6

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

318

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

474-481

1 reference

Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Acyclic nucleoside phosphonates: a new dimension to the chemotherapy of DNA virus and retrovirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Measurement of the respiratory volumes of laboratory animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

In vitro activity of potential anti-poxvirus agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.11.015

10.1016/J.VIROL.2003.11.015

7 January 2021

Identifiers

DOI

1 reference

6 December 2017

1 reference